Abstracts tagged "Comorbidity"

Abstract Number: 0183 • ACR Convergence 2020
Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry
Toshihiro Matsui¹, Naonobu Sugiyama², Tsutomu Kawaguchi², Aosa Kamezaki², Shigeyuki Toyoizumi³, Fujio Matsuyama⁴, Tatsunori Murata⁴, Yukitomo Urata⁵, Kimito Kawahata⁶ and Shigeto Tohma⁷, ¹Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer R&D Japan G.K., Tokyo, Japan, ⁴CRECON Medical Assessment Inc, Tokyo, Japan, ⁵Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, ⁶Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
Abstract Number: 0963 • ACR Convergence 2020
Chronic Obstructive Pulmonary Disease Associated with Prolonged Opiate Use, Increased Short-Term Complications and the Need for Revision Surgery Following Total Knee Arthroplasty
Jillian Glasser¹, Nicholas Lemme², Daniel Yang², Edward Testa², Alan Daniels³ and Valentin Antoci³, ¹University Orthopedics Inc, East Providence, RI, ²Warren Alpert School of Medicine, Providence, RI, ³Warren Alpert School of Medicine, East Providence, RI
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a condition which causes a substantial burden to patients, physicians, and the healthcare system at large. Medical comorbidities…
Abstract Number: 1727 • ACR Convergence 2020
Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
Samantha Rodriguez-Muguruza¹, Bernard Combe², Oliver Valero³, Francis Guillemin⁴, Alejandro Olivé-Marqués⁵, Bruno Fautrel⁶, Ramon Fontova¹ and Cédric Lukas⁷, ¹Joan XXIII Hospital, Tarragona, Spain, ²University of Montpellier, Montpellier, France, ³Department of Statistics, Autonoma de Barcelona University, Barcelona, Spain, ⁴Universite de Lorraine CIC INSERM, Nancy, France, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: to determine and characterize fatigue trajectories over 10 years of follow-up in a cohort of early RA patients. Methods: We selected patients fulfilling the 2010…
Abstract Number: 0190 • ACR Convergence 2020
Hepatic Steatosis in Rheumatoid Arthritis: Frequency and Disease-Related Contributors
Jun Lee¹, Galina Lagos², Joan Bathon¹ and Jon Giles¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Nonalcoholic fatty liver disease (NAFLD), a spectrum of disorders characterized by the presence of hepatic steatosis, is the most common liver disorder in western…
Abstract Number: 1021 • ACR Convergence 2020
Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Romy Kallas¹, Jessica Li², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Medical Institution, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Multiple variables are known to contribute to development of organ damage in SLE patients, including prednisone use and ethnicity. The aim of this study…
Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 0215 • ACR Convergence 2020
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Ernest Choy¹, Iain McInnes², John Cush³, Jacob Aelion⁴, William Rigby⁵, Yanna Song⁶, Sebastian Meerwein⁷, John Liu⁸, Nasser Khan⁸, Jessica Suboticki⁸ and Alexander Cohen⁹, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Texas Southwestern Medical School, Dallas, TX, ⁴Arthritis Clinic PLLC, Jackson, ⁵Dartmouth College, Norwichi, VT, ⁶AbbVie Inc., North Chicago,, IL, ⁷Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
Abstract Number: 1044 • ACR Convergence 2020
Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
Lara Sanchez-Bilbao¹, David Martinez-Lopez², Inigo Gonzalez-Mazon³, Maria José García-García⁴, Montserrat Rivero-Tirado⁴, Beatriz Castro⁴, Javier Crespo⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in…
Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Hanna Källmark¹, Birgitta Gullstrand², Johanna Nagel³, Jon Einarsson¹, Göran Jönsson⁴, Fredrik Kahn⁵, Robin Kahn⁶, Anders Bangtsson², Tomas Bergström⁷ and Meliha Kapetanovic¹, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden and Skåne University Hospital Sweden., Lund, Sweden, ²Department of Rheumatology, Clinical Sciences, Lund University Sweden, Lund, Sweden, ³Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ⁵Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden; Wallenberg Centre of Molecular Medicine, Lund University, Lund, Sweden, ⁷Department of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…
Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Kevin Real¹, Michael Duryee ¹, Patrick Opperman ¹, Evan Ryan ¹, Logan Duryee ¹, James O'Dell ², Ted Mikuls ², Daniel Anderson ¹ and Geoffrey Thiele ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…
Abstract Number: 2070 • 2019 ACR/ARP Annual Meeting
Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry
Sofia Pedro¹, Rebecca Schumacher ¹, Alyssa Dominique ², Yomei Shaw ¹, Kristin Wipfler ¹ and Kaleb Michaud ³, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: The burden of co-morbid conditions can impact the overall quality of life in patients with RA and OA. However, the presence of common co-morbidities…
Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Min Kyung Chung ¹, Jin Su Park ², Hyun Sun Lim ², Chan Hee Lee ² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…
Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2332 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Hafis Muhammed¹, Durga P Misra ¹, Sujata Ganguly ¹, Sarit Sekhar Pattanaik ¹, Saurabh Chaturvedi ¹, Harshit Singh ¹, Mohit K Rai ¹, Anamika Anuja ¹, Namita Mohindra ¹, Neeraj Jain ¹, Sudeep Kumar ¹ and Vikas Agarwal ¹, ¹SGPGI, Lucknow, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis(RA) patients have increased cardiovascular(CV) risk with no data on CV risk scores in Indian patients.The primary objective was to study prevalence of…
Abstract Number: 2465 • 2019 ACR/ARP Annual Meeting
Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis
Didem Erdem¹, Halise Hande Gezer ², Sevtap Acer Kasman ¹ and Mehmet Tuncay Duruoz ¹, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey
Background/Purpose: The Self‐Administered Comorbidity Questionnaire (SCQ) is a self-report questionnaire. It assesses 13 common medical conditions and the impact of comorbidities on functional status (1).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.